Abiomed Inc. (ABMD) News
Filter ABMD News Items
ABMD News Results
|Loading, please wait...|
ABMD News Highlights
- For ABMD, its 30 day story count is now at 8.
- Over the past 21 days, the trend for ABMD's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ABMD are JNJ, ACT and FLEX.
Latest ABMD News From Around the Web
Below are the latest news stories about ABIOMED INC that investors may wish to consider to help them evaluate ABMD as an investment opportunity.
DANVERS, Mass., December 21, 2022--Abiomed Announces First Patients Enrolled in FDA Pivotal Trial for Impella ECP, World’s Smallest Heart Pump
S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions.
In this article, we discuss the 10 best performing stocks in November. If you want to read about some more best performing stocks in November, go directly to 5 Best Performing Stocks in November. After the eventful month of October, which is widely known for stock market crashes, the United States (US) stock market jumped […]
Looking to start an after-tax-funded individual retirement account?
Abiomed (ABMD) ticked up 1% in premarket trading after the antitrust waiting period for its sale to Johnson & Johnson (JNJ) expired.The required waiting period under the HSR act expired…
Johnson & Johnson (NYSE: JNJ) is in the midst of a transition. One way the business can accelerate its plans for growth is via acquisitions, and Johnson & Johnson has been busy on that front of late. Horizon Therapeutics Public (NASDAQ: HZNP), a healthcare business that makes medicines to treat autoimmune and inflammatory diseases, issued a press release on Nov. 29 stating that it is in "preliminary discussions" regarding a potential acquisition of its business.
DANVERS, Mass., December 05, 2022--Abiomed announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist.
Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.